Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The pooled prevalence of GERD in the Indian population is 15.6 %
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Around 7% of the Indian population suffers from IBS
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Subscribe To Our Newsletter & Stay Updated